Genetic variants of the nuclear factor erythroid 2-related factor 2/antioxidant reaction element pathway on the risk of antituberculosis drug-induced liver injury: a systematic review.
Zhuolu HaoMeiling ZhangXinyu ChenMin ZhuBing HanYiwen HeHonggang YiShao-Wen TangPublished in: Pharmacogenomics (2023)
Aim: To evaluate the effects of genetic variants in the nuclear factor erythroid 2-related factor 2/antioxidant reaction element signaling pathway on antituberculosis drug-induced liver injury (AT-DILI) susceptibility. Methods: The PubMed, Embase, Cochrane, Web of Science, China National Knowledge Infrastructure and Wanfang databases were searched from inception to April 2022. Results: Seven case-control studies with 4676 patients were included. Six genes with 35 SNPs in the pathway have been reported. Among 17 SNPs reported in two or more studies, the meta-analysis indicated that only one SNP (rs3735656 in MAFK ) was significantly associated with a decreased risk for AT-DILI under the dominant model (odds ratio: 0.636; 95% CI: 0.519-0.780; p < 0.001). Conclusion: SNP rs3735656 in the MAFK gene was significantly associated with the risk of AT-DILI.
Keyphrases
- nuclear factor
- case control
- genome wide
- drug induced
- toll like receptor
- dna methylation
- end stage renal disease
- signaling pathway
- oxidative stress
- systematic review
- newly diagnosed
- chronic kidney disease
- ejection fraction
- copy number
- public health
- anti inflammatory
- quality improvement
- epithelial mesenchymal transition
- gene expression
- randomized controlled trial
- adverse drug
- pi k akt
- big data
- artificial intelligence
- peritoneal dialysis
- transcription factor
- meta analyses